Mirtazapina Sandoz (Mirtazapine)

Mirtazapine works by antagonizing central presynaptic α2‑adrenergic receptors and blocking postsynaptic 5‑HT2, 5‑HT3 and H1 receptors. This dual action increases the release of norepinephrine and serotonin, producing an antidepressant effect.

The dosage of Mirtazapina Sandoz is individualized. The prescribing clinician determines the appropriate starting dose and any subsequent titration based on the patient’s clinical response, tolerability, and overall health status.

Safety data for mirtazapine in pregnancy and lactation are limited. It is generally not recommended unless the potential benefit outweighs the risk. Clinicians should evaluate each case carefully and discuss possible risks with the patient.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike selective serotonin reuptake inhibitors, mirtazapine has a distinct receptor profile that often causes sedation and weight gain, making it useful for patients with insomnia or poor appetite. It does not act as a serotonin reuptake inhibitor, which may reduce certain side‑effects seen with SSRIs.

Store the product at ambient temperature below 25 °C in the original packaging. Protect it from moisture and direct sunlight, and keep it out of reach of children.

Mirtazapina Sandoz is taken orally, usually once daily in the evening, with or without food. Tablets should be swallowed whole and used exactly as prescribed by the healthcare professional.

Serious adverse events include agranulocytosis, severe neutropenia, emergence of suicidal thoughts or behaviors, and severe hypersensitivity reactions such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if any of these occur.

Individuals with known hypersensitivity to mirtazapine, those currently taking monoamine oxidase inhibitors, or patients with uncontrolled severe hepatic impairment should avoid this medication. A qualified clinician must assess suitability before prescribing.